Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Here’s What Happened

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $18.70, but opened at $17.83. Daiichi Sankyo shares last traded at $18.8850, with a volume of 54,170 shares changing hands.

Analyst Ratings Changes

Separately, Zacks Research downgraded Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Daiichi Sankyo has a consensus rating of “Moderate Buy”.

Daiichi Sankyo Price Performance

The company has a debt-to-equity ratio of 0.06, a current ratio of 2.31 and a quick ratio of 1.60. The company has a market cap of $35.46 billion and a PE ratio of 17.66. The stock’s 50-day moving average is $21.60 and its 200 day moving average is $23.44.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Thursday, January 29th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.05. Daiichi Sankyo had a return on equity of 18.39% and a net margin of 15.40%.The firm had revenue of $3.65 billion for the quarter, compared to the consensus estimate of $3.88 billion. On average, equities analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.73 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.